The Peptide AppThe Peptide App

The Peptide AppField Guide · Healing SeriesSpecimen No. 27

Healing Category

PNC-27

THE CANCER TERMINATOR

HDM-2 Binding Peptide

PNC-27 is a synthetic peptide designed to selectively kill cancer cells while leaving healthy cells unharmed. It works by binding to HDM-2, a protein that cancer cells overexpress on their surface, and then forming pores in their membranes. This liberates the p53 tumor suppressor, allowing it to trigger cancer cell death. It's being researched for various cancers.

PNC-27
PNC-27
PNC-27

PNC-27 Evidence Snapshot

How these guides are reviewed
Regulatory status
Not FDA approved · research use only
Dosing guidance
Reviewed by our clinical team
Linked evidence
7 research sources
Content updated
May 8, 2026

Dose and schedule recommendations shown below come from The Peptide App Clinical Team. Research links are provided so readers can inspect the supporting evidence directly. Review the sources.

Quick Answers About PNC-27

Is PNC-27 FDA approved?

No. This profile records PNC-27 as not FDA approved and for research use only.

More context

Review the regulatory and source details on this page for the current context.

What dose does The Peptide App Clinical Team recommend for PNC-27?

Dose: 250 mcg daily (research protocol).

More context

Schedule: daily. Cycle: 6 weeks on, 8 weeks off. This is clinical-team guidance for reference and does not replace individualized instructions from a licensed clinician.

What research supports this PNC-27 guide?

This guide links to 7 curated or current research sources.

More context

Open the research section to inspect the source titles, publication details, study types, and available abstracts directly.

Review the PNC-27 research sources

Studied Effects & Mechanisms

HDM-2 Binding

Binds to HDM-2 protein overexpressed on cancer cells

p53 Liberation

Frees p53 tumor suppressor to activate apoptosis

Membrane Pores

Forms channels in cancer cell membranes causing necrosis

Selectivity

Spares healthy cells lacking HDM-2 overexpression

Clinical & Research Context

Those exploring adjunctive cancer therapies
People interested in targeted treatments
Those with cancers overexpressing HDM-2
Anyone researching selective anti-cancer peptides

Research-Market Price Snapshot

A compact market signal for this profile. The dedicated pricing page owns vendor, vial-size, and price-per-mg comparisons.

Updated Jul 16, 2026

Vendors
13
Listings
16
Observed range
$35$326
Compare all PNC-27 prices →

PNC-27 Research

Live PubMed intelligence from the research crawler

PMID 26663795HumanRelevance 72Extracted

OBJECTIVE: Despite an 80% response rate to chemotherapy, epithelial ovarian cancer has the highest case fatality rate of all gynecologic malignancies. Several studies have shown the efficiency of anticancer peptides PNC-27 and PNC-28 in killing a variety of cancer cells selectively in vitro and in vivo. The purpose of this study was to evaluate the efficacy of PNC-27 against human primary epithelial ovarian cancer. METHODS: We established primary cultures of freshly isolated epithelial ovarian cancer cells from patients with newly diagnosed ovarian cystadenocarcinomas. Two cell lines were obtained, one from mucinous cystadenocarcinoma, and the other from high-grade papillary serous carcinoma. The cancerous properties of these cells were characterized in vitro morphologically, by their growth requirements and serum independence. Treatment effects with PNC-27 were followed qualitatively by light microscopy, and quantitatively by measuring inhibition of cell growth using the MTT cell proliferation assay and direct cytotoxicity by measuring lactate dehydrogenase (LDH). RESULTS: PNC-27 inhibits in a dose-dependent manner the growth of and is cytotoxic to human primary cancer cells that had been freshly isolated from two ovarian epithelial cancers. The results further show that the control peptide PNC-29 has no effect on the primary cancer cells. Our results also show that PNC-27 is cytotoxic to cells from long-established and chemotherapy-resistant human ovarian cancer cell lines. CONCLUSION: These findings show, for the first time, the efficacy of PNC-27 on freshly isolated, primary human cancer cells. Our results indicate the potential of PNC-27 peptide as an efficient alternative treatment of previously untreated ovarian cancer as well as for ovarian cancers that have become resistant to present chemotherapies.

Efficacy evidence
PMID 40750238In VitroRelevance 66

OBJECTIVE: The peptide PNC-27 has been found to kill many different endodermal solid tissue and hematopoietic cancer cells but has no effect on normal cells. The mechanism involves binding to the HDM-2 protein, which is expressed in the membranes of cancer cells but not in normal (untransformed) cells. Our objectives in the current study are to determine 1) if PNC-27 is lethal to squamous cervical epithelial cancer cells but not to untransformed squamous cervical cells; 2) if membrane-bound HDM-2 is expressed uniquely in cervical cancer cells; and 3) whether HDM-2 is stable for detection in different types of preservative solutions. METHODS: We determined dose response curves for incubation of PNC-27 with the human squamous cervical cancer cell line HTB-35 (also called SiHa cells) and with the untransformed human squamous cervical cell line, PCS-480. Cell viability was determined using the MTT and LDH release assays. Finally, slot blots and flow cytometry were used to determine membrane expression of HDM-2 using a polyclonal anti-HDM-2 antibody. RESULTS: We found that PNC-27 is cytotoxic even at low doses (IC50=12.4 μM) to the human HTB-35 cervical cancer squamous epithelial cell line but not to a counterpart normal human PCS-480 cell line. We found that HTB-35 cells express high levels of HDM-2 proteins in their membranes both in cell culture and in alcoholic preservative solutions but that the normal PCS-480 cells do not. Consistent with previous results, the data suggest that cervical cancer cells express HDM-2 in their membranes and that this is the target for PNC-27. CONCLUSIONS: PNC-27 kills cervical squamous cancer but not normal cervical cells due to the unique expression of HDM-2 in the cervical squamous cell membranes. Thus, PNC-27 may be an effective drug against this cancer. Our results further suggest that the expression of membrane-bound HDM-2 on cervical cancer cells is stable both in cell culture media and in alcoholic preservative fluid.

PMID 28667027AnimalRelevance 65

OBJECTIVES: Paclitaxel is widely used in the treatment of gynecologic malignancies. It targets tumor cells in the M phase of the cell cycle. Cells in other phases survive the insult and repopulate the tumor. PNC-27 is a peptide synthesized of amino acids of the p53-MDM-2 binding domain. It kills various cancer cell lines in a dose-dependent manner. The goal of this study is to assess ovarian cancer cells' sensitivity to PNC-27 after surviving exposure to paclitaxel and to investigate the potential for synergy between PNC-27 and paclitaxel in the treatment of ovarian cancer. METHODS: The impact of exposure to paclitaxel on the surface expression of MDM-2 was assessed with the use of flow cytometry. For measurement of cytotoxicity in vitro, ID8 cells were exposed to paclitaxel for 12 hours in various concentrations. At 12 hours, the drug containing media was removed and the cells were cultured in media containing various concentrations of PNC-27 for 24 hours. Viability was assessed with the use of an MTT assay. Survival fractions were plotted against drug concentrations and the data were fit to logistic dose-response curves. Isoeffective combinations were used to create isobolograms. The combined treatment with weekly paclitaxel and PNC-27 was tested in an intraperitoneal mouse model of ovarian cancer (ID8). RESULTS: Exposure to paclitaxel rendered incomplete time-dependent killing, while PNC-27 mediated comprehensive, dose-dependent killing of ID8 cells. The cytotoxic effect of PNC-27 was dependent on its binding to MDM-2. Blocking MDM-2 inhibited the killing by PNC-27. ID8 cells surviving paclitaxel demonstrated increased expression of MDM-2 and increased susceptibility to PNC-27. Isobologram for dose combinations that were isoeffective indicates synergistic effect between the 2 agents (Combination index <1). In an in vivo model of ovarian cancer (ID8), the addition of PNC-27 to weekly paclitaxel administration significantly reduces tumor growth. CONCLUSIONS: These data demonstrate synergism between PNC-27 and paclitaxel. PNC-27 could target cells surviving paclitaxel and improve its antitumor effect.

PMID 36311203In VitroRelevance 62

OBJECTIVES: Superparamagnetic iron oxide nanoparticles (SPIONs) have been considered promising non-invasive imaging tools in medicine. However, their high surface energy leads to NPs aggregation, while non-targeted SPIONs can cause cytotoxic effects on normal cells. In this work, we evaluated the in vitro potential of polyethyleneimine (PEI)-SPIONs targeted by PNC-27 peptide as a double targeting agent throughout early cancer diagnosis. MATERIALS AND METHODS: Initially, PEI was conjugated to PNC-27 with HDM-2-binding domain. Then, SPIONs were loaded into PEI-PNC-27 through the ligand exchange method. The physicochemical characteristics of the synthesized NPs were evaluated. The cytotoxicity and targeting efficiency were assayed against HT-29 and CT-26 cell lines along with NIH-3t3 as normal cells by MTT method and Prussian blue staining test, respectively. RESULTS: The mean diameter of synthesized carriers was obtained in the range of 86.6 - 116.1 nm with a positive charge. According to the cytotoxicity results, the binding and uptake abilities of the PNC-27 peptide by cancer cells were significantly higher than that of the NIH-3t3 cells. However, the results were indicative of the more toxic impacts of targeted synthesized NPs against CT-26 cancer cell line when being compared with HT-29 cells, which may be caused by the different cytotoxicity mechanisms of NPs. In addition, the targeted carriers and SPIONs were present inside and around the cells with HDM-2 expression along with only a few non-targeted vectors, while displaying no appearance throughout the normal cell. CONCLUSION: The results indicated the efficiency of targeted PEI-coated SPIONs for cancer diagnostic applications.

PMID 32878773In VitroRelevance 58

BACKGROUND/AIM: Anticancer peptide PNC-27 binds to HDM-2 protein on cancer cell membranes inducing the formation of cytotoxic transmembrane pores. Herein, we investigated HDM-2 membrane expression and the effect of PNC-27 treatment on human non-stem cell acute myelogenous leukemia cell lines: U937, acute monocytic leukemia; OCI-AML3, acute myelomonocytic leukemia and HL60, acute promyelocytic leukemia. MATERIALS AND METHODS: We measured cell surface membrane expression of HDM-2 using flow cytometry. Cell viability was assessed using MTT assay while direct cytotoxicity was measured by lactate dehydrogenase (LDH) release and induction of apoptotic markers annexin V and caspase-3. RESULTS: HDM-2 is expressed at high levels in membranes of U937, OCI-AML3 and HL-60 cells. PNC-27 can bind to membrane HDM-2 to induce cell necrosis and LDH release within 4 h. CONCLUSION: Targeting membrane HDM-2 can be a potential strategy to treat leukemia. PNC-27 targeting membrane HDM-2 demonstrated significant anti-leukemia activity in a variety of leukemic cell lines.

PMID 38802154In VitroRelevance 57

OBJECTIVE: We have previously shown that the anti-cancer peptide PNC-27 kills cancer cells by co-localizing with membrane-expressed HDM-2, resulting in transmembrane pore formation causing extrusion of intracellular contents. We have also observed cancer cell mitochondrial disruption in PNC-27-treated cancer cells. Our objectives are to determine: 1. if PNC-27 binds to the p53 binding site of HDM-2 (residues 1-109) in the cancer cell membrane and 2. if this peptide causes selective disruption of cancer cell mitochondria. METHODS: For aim 1, we incubated MIA-PaCa-2 human pancreatic carcinoma cells with PNC-27 in the presence of a monoclonal antibody against the amino terminal p53 binding site of HDM-2 to determine if it, but not negative control immune serum, blocks PNC-27-induced tumor cell necrosis. For the second aim, we incubated these cells with PNC-27 in the presence of two specific dyes that highlight normal organelle function: mitotracker for mitochondria and lysotracker for lysosomes. We also performed immuno-electron microscopy (IEM) with gold-labeled anti-PNC-27 antibody on the mitochondria of these cells treated with PNC-27. RESULTS: Monoclonal antibody to the p53 binding site of HDM-2 blocks PNC-27-induced cancer cell necrosis, whereas negative control immune serum does not. The mitochondria of PNC-27-treated cancer cells fail to retain mitotracker dye while their lysosomes retain lysotracker dye. IEM of the mitochondria cancer cells reveals gold particles present on the mitochondrial membranes. CONCLUSIONS: PNC-27 binds to the p53 binding site of HDM-2 (residues 1-109) inducing transmembrane pore formation and cancer cell necrosis. Furthermore, this peptide enters cancer cells and binds to the membranes of mitochondria, resulting in their disruption.

Related Peptides

CJC-1295 (no DAC)

THE GH SUSTAINER
BGood
Growth Hormone & Musculoskeletal Support · Anti-Aging & LongevityHealing · Growth Hormone & Musculoskeletal SupportDose100 mcgCycle8 weeks on, 8 weeks offKicks inSleep improvements within 1-2 weeks; body...

Long-acting growth hormone releaser for muscle, recovery and anti-aging

from $3/mg · 74 vendorsNº 002 / 006

BPC-157

THE HEALER
AHigh
Accelerated Healing · Neurological SupportHealing · Accelerated HealingDose250 mcgCycle4-8 weeks on, then equal breakKicks inGut issues often improve faster - many...

Accelerates healing of tendons, ligaments, gut, and muscles throughout your body.

from $1.99/mg · 122 vendorsNº 001 / 006

Melanotan II

THE TANNING PEPTIDE
CModerate
Skin Pigmentation · Sexual & Reproductive HealthMetabolic · Skin PigmentationDose250 mcgCycleLoading phase: daily for 2-3 weeks....Kicks inTanning typically visible within 1-2 weeks.

Develop a natural-looking tan with minimal sun exposure

from $1.36/mg · 56 vendorsNº 003 / 006

MOTS-c

THE METABOLIC MESSENGER
BGood
Metabolic Modulator · Mitochondrial SupportMetabolic · Metabolic ModulatorDose5 mgCycle8-12 weeks on, 4 weeks offKicks inMetabolic improvements may be measurable...

Exercise in a peptide - boost metabolism without the treadmill

from $0.75/mg · 110 vendorsNº 004 / 006

SS-31

THE MITOCHONDRIAL OPTIMIZER
BGood
Cardiovascular Support · Neurological SupportHealing · Cardiovascular SupportDose5 mgCycle6 weeks on, 8 weeks offKicks inEnergy improvements may be noticed within...

Directly target and repair your mitochondria

from $1.60/mg · 53 vendorsNº 006 / 006

Selank

THE ANXIETY REDUCER
AHigh
Nootropic · Anxiety ManagementCognitive · NootropicDose400 mcgCycle6 weeks on, 6 weeks offKicks inAnti-anxiety effects often noticed within...

Calms anxiety while improving focus and cognitive function for balanced mood.

from $1.10/mg · 74 vendorsNº 005 / 006